MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$14,949K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of inve...
Proceeds from issuance of common...
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchases of investments
Operating lease liabilities
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
41,499
-
-
-
Net loss
-17,964
-19,042
-18,985
-18,234
Depreciation expense
405
383
361
349
Stock-based compensation expense
2,214
2,181
3,091
3,911
Non-cash operating lease expense
276
273
265
259
Net amortization of premiums and accretion of discounts on investments
-61
-161
-130
34
Prepaid expenses and other current assets
51
-380
756
223
Accounts payable
-214
-1,202
1,281
-9
Accrued expenses and other liabilities
-
-
-3,353
-
Accrued expenses and other current liabilities
711
-506
-
1,972
Operating lease liabilities
-300
-294
-280
-274
Other assets
-
-
-137
-
Net cash used in operating activities
-14,862
-20,538
-15,237
-12,283
Purchases of investments
9,966
16,859
13,257
33,190
Proceeds from maturities of investments
25,000
30,000
35,000
40,000
Purchases of property and equipment
87
14
219
899
Net cash provided by investing activities
14,947
13,127
21,524
5,911
Proceeds from issuance of common stock under at-the-market offering
7,299
-
-
-
Proceeds from exercise of common stock options
8
-
0
0
Payments of issuance costs
4
-
-
-
Payments of tax withholdings related to vesting of restricted stock units
34
33
192
117
Net cash provided by (used in) financing activities
7,269
-33
-192
-117
Net (decrease) increase in cash, cash equivalents, and restricted cash
7,354
-7,444
6,095
-6,489
Cash, cash equivalents and restricted cash at beginning of period
34,258
41,702
35,607
40,016
Cash, cash equivalents and restricted cash at end of period
41,612
34,258
41,702
35,607
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities
0
-
-
-
Issuance of common stock upon exercise of pre-funded warrants
7
-
-
-
Restricted cash
195
-
-
-
Total cash, cash equivalents, and restricted cash
41,612
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of investments
$25,000K
(-66.44%↓ Y/Y)
Proceeds from issuance of
common stock under...
$7,299K
Proceeds from exercise of
common stock options
$8K
(700.00%↑ Y/Y)
Net cash provided by
investing activities
$14,947K
(-61.34%↓ Y/Y)
Net cash provided by
(used in) financing...
$7,269K
(1752.05%↑ Y/Y)
Canceled cashflow
$10,053K
Canceled cashflow
$38K
Net (decrease)
increase in cash, cash...
$7,354K
(253.56%↑ Y/Y)
Canceled cashflow
$14,862K
Purchases of investments
$9,966K
(-71.75%↓ Y/Y)
Purchases of property and
equipment
$87K
(-84.21%↓ Y/Y)
Stock-based compensation
expense
$2,214K
(-71.31%↓ Y/Y)
Accrued expenses and
other current...
$711K
(114.68%↑ Y/Y)
Depreciation expense
$405K
(-37.31%↓ Y/Y)
Non-cash operating lease
expense
$276K
(-45.13%↓ Y/Y)
Net amortization of
premiums and accretion of...
-$61K
(-111.44%↓ Y/Y)
Payments of tax
withholdings related to...
$34K
(-92.29%↓ Y/Y)
Payments of issuance
costs
$4K
Net cash used in
operating activities
-$14,862K
(58.88%↑ Y/Y)
Canceled cashflow
$3,667K
Net loss
-$17,964K
(55.85%↑ Y/Y)
Operating lease
liabilities
-$300K
(21.47%↑ Y/Y)
Accounts payable
-$214K
(-181.06%↓ Y/Y)
Prepaid expenses and
other current assets
$51K
(104.36%↑ Y/Y)
Buy us a coffee
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)